AbbVie Inc. (ABBV)
Data as of , from SEC Form 4 filings.
See up to 3 months of ABBV. The 7-day demo opens the 1M and 3M ranges and puts ABBV on your watchlist.
Start 7-day demoLatest ABBV insider trades
- Nicholas Donoghoe - OfficerOpen-market sale$8.18M
David Ryan Purdue - OfficerOpen-market sale$1.22M
About AbbVie Inc. (ABBV)
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
- NORTH CHICAGO, IL
- 57,000
- 2012
- XNYS
ABBV Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 32,710 | $8.18M |
| Grant or award | 2 | 188 | |
| Option exercise | 2 | 65,420 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ABBV insider transactions (Form 4)
7761 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 2 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Perry C. Siatis - Officer | Option exercise | Common Stock, $0.01 par value | 7,314 | $149.62 | $1.09M | |
| Perry C. Siatis - Officer | Option exercise | Common Stock, $0.01 par value | 7,775 | $175.28 | $1.36M | |
| Perry C. Siatis - Officer | Option exercise | Common Stock, $0.01 par value | 7,292 | $192.86 | $1.41M | |
| Perry C. Siatis - Officer | Open-market sale | Common Stock, $0.01 par value | 22,381 | $230.00 | $5.15M | |
| Perry C. Siatis - Officer | Option exercise | Option (Right to buy) | 7,314 | $149.62 | $1.09M | |
| Perry C. Siatis - Officer | Option exercise | Option (Right to buy) | 7,775 | $175.28 | $1.36M | |
| Perry C. Siatis - Officer | Option exercise | Option (Right to buy) | 7,292 | $192.86 | $1.41M | |
| Roopal Thakkar - Officer | Grant or award | Common Stock, $0.01 par value | 6,015 footnote F1 | $0.00 | - | |
| Roopal Thakkar - Officer | Grant or award | Common Stock, $0.01 par value | 2,138 footnote F2 | $0.00 | - | |
| Roopal Thakkar - Officer | Grant or award | Common Stock, $0.01 par value | 3,346 footnote F3 | $0.00 | - | |
| Roopal Thakkar - Officer | Grant or award | Common Stock, $0.01 par value | 6,638 footnote F4 | $0.00 | - | |
| Roopal Thakkar - Officer | Grant or award | Option (Right to buy) | 21,937 | $0.00 | - | |
| ||||||
| David Ryan Purdue - Officer | Grant or award | Common Stock, $0.01 par value | 2,505 footnote F1 | $0.00 | - | |
| David Ryan Purdue - Officer | Grant or award | Common Stock, $0.01 par value | 890 footnote F2 | $0.00 | - | |
| David Ryan Purdue - Officer | Grant or award | Common Stock, $0.01 par value | 1,292 footnote F3 | $0.00 | - | |
| David Ryan Purdue - Officer | Grant or award | Common Stock, $0.01 par value | 1,384 footnote F4 | $0.00 | - | |
| David Ryan Purdue - Officer | Grant or award | Option (Right to buy) | 4,875 | $0.00 | - | |
| ||||||
 Jeffrey Ryan Stewart - Officer | Grant or award | Common Stock, $0.01 par value | 26,063 footnote F1 | $0.00 | - | |
| Jeffrey Ryan Stewart - Officer | Grant or award | Common Stock, $0.01 par value | 9,266 footnote F2 | $0.00 | - | |
| Jeffrey Ryan Stewart - Officer | Grant or award | Common Stock, $0.01 par value | 9,432 footnote F3 | $0.00 | - | |
| Jeffrey Ryan Stewart - Officer | Grant or award | Common Stock, $0.01 par value | 8,988 footnote F4 | $0.00 | - | |
| Jeffrey Ryan Stewart - Officer | Grant or award | Option (Right to Buy) | 26,812 | $0.00 | - | |
| ||||||
| Perry C. Siatis - Officer | Grant or award | Common Stock, $0.01 par value | 16,290 footnote F1 | $0.00 | - | |
| Perry C. Siatis - Officer | Grant or award | Common Stock, $0.01 par value | 5,792 footnote F2 | $0.00 | - | |
| Perry C. Siatis - Officer | Grant or award | Common Stock, $0.01 par value | 5,628 footnote F3 | $0.00 | - | |
| Perry C. Siatis - Officer | Grant or award | Common Stock, $0.01 par value | 5,808 footnote F4 | $0.00 | - | |
| Perry C. Siatis - Officer | Grant or award | Option (Right to buy) | 19,500 | $0.00 | - | |
| ||||||
| Azita Saleki-Gerhardt - Officer | Grant or award | Common Stock, $0.01 par value | 6,638 footnote F4 | $0.00 | - | |
| Azita Saleki-Gerhardt - Officer | Grant or award | Option (Right to Buy) | 20,312 | $0.00 | - | |
| Azita Saleki-Gerhardt - Officer | Grant or award | Common Stock, $0.01 par value | 17,041 footnote F1 | $0.00 | - | |
| Azita Saleki-Gerhardt - Officer | Grant or award | Common Stock, $0.01 par value | 6,058 footnote F2 | $0.00 | - | |
| Azita Saleki-Gerhardt - Officer | Grant or award | Common Stock, $0.01 par value | 7,074 footnote F3 | $0.00 | - | |
| ||||||
 Demetris D. Crum - Officer | Grant or award | Common Stock, $0.01 par value | 1,216 footnote F1 | $0.00 | - | |
| Demetris D. Crum - Officer | Grant or award | Common Stock, $0.01 par value | 1,244 footnote F2 | $0.00 | - | |
| Demetris D. Crum - Officer | Grant or award | Option (Right to buy) | 13,406 | $0.00 | - | |
| ||||||
| Nicholas Donoghoe - Officer | Grant or award | Common Stock, $0.01 par value | 13,031 footnote F1 | $0.00 | - | |
| Nicholas Donoghoe - Officer | Grant or award | Common Stock, $0.01 par value | 4,632 footnote F2 | $0.00 | - | |
| Nicholas Donoghoe - Officer | Grant or award | Common Stock, $0.01 par value | 5,172 footnote F3 | $0.00 | - | |
| Nicholas Donoghoe - Officer | Grant or award | Common Stock, $0.01 par value | 6,222 footnote F4 | $0.00 | - | |
| Nicholas Donoghoe - Officer | Grant or award | Option (Right to buy) | 20,312 | $0.00 | - | |
| ||||||
| Scott T. Reents - Officer | Grant or award | Common Stock, $0.01 par value | 25,062 footnote F1 | $0.00 | - | |
| Scott T. Reents - Officer | Grant or award | Common Stock, $0.01 par value | 8,910 footnote F2 | $0.00 | - | |
| Scott T. Reents - Officer | Grant or award | Common Stock, $0.01 par value | 7,606 footnote F3 | $0.00 | - | |
| Scott T. Reents - Officer | Grant or award | Common Stock, $0.01 par value | 7,260 footnote F4 | $0.00 | - | |
| Scott T. Reents - Officer | Grant or award | Option (Right to buy) | 21,937 | $0.00 | - | |
| ||||||
| Robert A. Michael - Officer | Grant or award | Common Stock, $0.01 par value | 33,833 footnote F1 | $0.00 | - | |
| Robert A. Michael - Officer | Grant or award | Common Stock, $0.01 par value | 12,030 footnote F2 | $0.00 | - | |
| Robert A. Michael - Officer | Grant or award | Common Stock, $0.01 par value | 14,452 footnote F3 | $0.00 | - | |
| Robert A. Michael - Officer | Grant or award | Common Stock, $0.01 par value | 22,124 footnote F4 | $0.00 | - | |
| Robert A. Michael - Officer | Grant or award | Option (Right to Buy) | 81,251 | $0.00 | - | |
| ||||||
 Susan E. Quaggin | Grant or award | Stock Equivalent Units | 67 | $231.54 | $16K | |
| Robert J. Alpern | Grant or award | Stock Equivalent Units | 33 | $231.54 | $8K | |
 Edward J. Rapp | Grant or award | Stock Equivalent Units | 145 | $231.54 | $34K | |
| Azita Saleki-Gerhardt - Officer | Option exercise | Common Stock, $0.01 par value | 42,370 | $54.86 | $2.32M | |
| Azita Saleki-Gerhardt - Officer | Open-market sale | Common Stock, $0.01 par value | 42,370 | $198.42 | $8.41M | |
| Azita Saleki-Gerhardt - Officer | Option exercise | Option (Right to Buy) | 42,370 | $54.86 | $2.32M | |
| Nicholas Donoghoe - Officer | Open-market sale | Common Stock, $0.01 par value | 3,234 | $198.27 | $641K | |
| Nicholas Donoghoe - Officer | Open-market sale | Common Stock, $0.01 par value | 10,061 | $198.59 | $2.00M | |
| Susan E. Quaggin | Grant or award | Stock Equivalent Units | 81 | $185.62 | $15K | |
| Robert J. Alpern | Grant or award | Stock Equivalent Units | 40 | $185.62 | $7K | |
| Edward J. Rapp | Grant or award | Stock Equivalent Units | 177 | $185.62 | $33K | |
| Thomas C. Freyman | Grant or award | Common Stock, $0.01 par value | 1,203 | $0.00 | - | |
| Frederick H. Waddell | Grant or award | Common Stock, $0.01 par value | 1,203 | $0.00 | - | |
| Thomas J. Falk | Grant or award | Common Stock, $0.01 par value | 1,203 | $0.00 | - | |
| Glenn F. Tilton | Grant or award | Common Stock, $0.01 par value | 1,203 | $0.00 | - | |
| Edward J. Rapp | Grant or award | Common Stock, $0.01 par value | 1,203 | $0.00 | - | |
 Roxanne S. Austin | Grant or award | Common Stock, $0.01 par value | 1,203 | $0.00 | - | |
| Richard A. Gonzalez | Gift | Common Stock, $0.01 par value | 2,450 | $0.00 | - | |
| Edward J. Rapp | Grant or award | Stock Equivalent Units | 155 | $209.52 | $32K | |
| Kevin K. Buckbee - Officer | Option exercise | Common Stock, $0.01 par value | 1,800 | $93.50 | $168K | |
| Kevin K. Buckbee - Officer | Open-market sale | Common Stock, $0.01 par value | 1,800 | $172.24 | $310K | |
| Kevin K. Buckbee - Officer | Option exercise | Option (Right to buy) | 1,800 | $93.50 | $168K | |
| Susan E. Quaggin | Grant or award | Stock Equivalent Units | 75 | $197.48 | $15K | |
| Robert J. Alpern | Grant or award | Stock Equivalent Units | 37 | $197.48 | $7K | |
| Richard A. Gonzalez - Officer | Gift | Common Stock, $0.01 par value | 5,243 | $0.00 | - | |
| Richard A. Gonzalez - Officer | Gift | Common Stock, $0.01 par value | 15,729 | $0.00 | - | |
| Richard A. Gonzalez - Officer | Gift | Common Stock, $0.01 par value | 36,698 | $0.00 | - | |
Item 2.02, 9.01
Item 7.01, 9.01
Item 8.01, 9.01
Item 8.01, 9.01
Recent ABBV Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| NICHOLAS DONOGHOE | Officer | 32,710 | $8.18M | View on EDGAR | |
| - | - | - | - |
Stock trades in ABBV disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
 Pete SessionsRepublican, TX-17 | Sale |
ABBV insider trading FAQ
What is the latest insider trade for ABBV?
AbbVie Inc. (ABBV) had 3 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for ABBV runs to 61 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ABBV stock?
No insider purchases of ABBV were filed in the last 90 days.
How many insiders are selling ABBV stock?
1 insider sale of ABBV was filed in the last 90 days, totaling $8.18M.
Where can I see ABBV SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ABBV Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Susan E. Quaggin view on EDGAR
- - Edward J. Rapp view on EDGAR
- - Nicholas Donoghoe view on EDGAR
- - Edward J. Rapp view on EDGAR
- - Susan E. Quaggin view on EDGAR
- - Thomas J. Falk view on EDGAR
- - Frederick H. Waddell view on EDGAR
- - Rebecca B. Roberts view on EDGAR
- - Edward J. Rapp view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ABBV's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ABBV with a 7-day demo
- ABBV on your watchlist
- Every ABBV Form 4 filing on record
- Up to 3 months of ABBV price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
